RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Corruption Risk: Responding to Critical Issues in the Pharmaceutical Industry

Corruption Risk: Responding to Critical Issues in the Pharmaceutical Industry

Posted 01 November 2010 | By

As regulators and law enforcement officials in the US and abroad shine brighter spotlights on the pharmaceutical industry, it is more important than ever for life sciences companies to have programs to evaluate, mitigate and monitor corruption risk. A robust anti-corruption compliance program provides a critical "rule book" for life sciences companies conducting business in today's global economy.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.